ArticleFEBS open bio2019
Knockdown of lncRNA MNX1-AS1 suppresses cell proliferation, migration, and invasion in prostate cancer.
Article in FEBS open bio, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Clinical significance of long noncoding RNA MNX1-AS1 in human cancers: a meta-analysis of cohort studies and bioinformatics analysis based on TCGA datasets.Bioengineered · 2021Pooled it
- Retraction Note: Silibinin suppresses epithelial-mesenchymal transition in human non-small cell lung cancer cells by restraining RHBDD1.Cellular & molecular biology letters · 2025Article
- MNX1-AS1, a c-Myc induced lncRNA, promotes the Warburg effect by regulating PKM2 nuclear translocation.Journal of experimental & clinical cancer research : CR · 2022Article
- Differences in Prostate Cancer Transcriptomes by Age at Diagnosis: Are Primary Tumors from Older Men Inherently Different?Cancer prevention research (Philadelphia, Pa.) · 2022Article
- Pan-Cancer Analysis IdentifiesCells · 2022Article
- lncRNA MNX1‑AS1 promotes prostate cancer progression through regulating miR‑2113/MDM2 axis.Molecular medicine reports · 2022Article
- Molecular Landscape of LncRNAs in Prostate Cancer: A focus on pathways and therapeutic targets for intervention.Journal of experimental & clinical cancer research : CR · 2022Review
- The Role of Long Non-Coding RNAs in Epithelial-Mesenchymal Transition-Related Signaling Pathways in Prostate Cancer.Frontiers in molecular biosciences · 2022Review
- Article
- LncRNA MNX1-AS1 promotes progression of intrahepatic cholangiocarcinoma through the MNX1/Hippo axis.Cell death & disease · 2020Article
- High expression of keratin 6C is associated with poor prognosis and accelerates cancer proliferation and migration by modulating epithelial-mesenchymal transition in lung adenocarcinoma.Genes & genomics · 2020Article
- LINC00152 promotes pancreatic cancer cell proliferation, migration and invasion via targeting miR-150.American journal of translational research · 2020Article
- Clinical effects and molecular mechanisms of lncRNA MNX1-AS1 in malignant tumors.American journal of translational research · 2020Article
- LncRNA MNX1-AS1 Contributes to Laryngeal Squamous Cell Carcinoma Growth and Migration by Regulating mir-744-5p/bcl9/β-Catenin Axis.Cell transplantationArticle
Corrections and comments
- Retraction · 2022-11-15Duplication of/in Image · Investigation by Third Party · Paper Mill · · see also: https://pubpeer.com/publications/F16DEDF138667343126EB2EE5CE4EC
- Retracted
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Altered expression of long non-coding RNAs (lncRNAs) has been reported in many malignancies, including prostate cancer. However, the role of lncRNA MNX1-AS1 in prostate cancer has not been reported. Here, we report that MNX1-AS1 is expressed in prostate cancer tissues and cells and that siRNA-mediated knockdown of MNX1-AS1 inhibits proliferation, migration, and invasion of prostate cancer DU145 and PC3 cells. In addition, down-regulation of MNX1-AS1 decreased expression of proliferating cell nuclear antigen, PH-3, N-cadherin, and vimentin, but enhanced expression of E-cadherin. In conclusion, this is the first report that knockdown of MNX1-AS1 suppresses prostate cancer cell proliferation, migration, and invasion. We believe that MNX1-AS1 may be a potential new therapeutic target for prostate cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.